NCT04557176 (TB SCRIPT) is a NA clinical trial of CRP, point-of-care assay in Tuberculosis, sponsored by University of California, San Francisco.

Who is sponsoring NCT04557176?

NCT04557176 is sponsored by University of California, San Francisco.

What drugs are being tested in NCT04557176?

Interventions in NCT04557176: CRP, point-of-care assay.

What condition does NCT04557176 study?

NCT04557176 studies Tuberculosis, Latent Tuberculosis, Tuberculosis Prevention, HIV.

Is NCT04557176 still recruiting?

NCT04557176 is currently active, enrolled. Last updated 10 June 2025.

Last reviewed 2025-06-10 · How we verify

NCT04557176: TB SCRIPT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TB Screening Improves Preventive Therapy Uptake

Active, enrolled NA Last updated 10 June 2025

What this trial tests

NA trial testing CRP, point-of-care assay in Tuberculosis in 1,719 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

16 November 2020

Primary endpoint
30 September 2025

30 September 2025

Quick facts

Lead sponsor	University of California, San Francisco
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	screening
Enrollment	1,719
Start date	16 November 2020
Primary completion	30 September 2025
Estimated completion	30 September 2025
Sites	1 location across Uganda

Drugs / interventions tested

CRP, point-of-care assay

Conditions studied

Tuberculosis — all drugs for Tuberculosis →
Latent Tuberculosis — all drugs for Latent Tuberculosis →
Tuberculosis Prevention — all drugs for Tuberculosis Prevention →
HIV — all drugs for HIV →

Sponsor

University of California, San Francisco

Who can join

18 and older, any sex, with Tuberculosis or Latent Tuberculosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

HIV-infected people have an increased risk of developing active tuberculosis (TB). To reduce the burden of TB among people living with HIV (PLHIV), the World Health Organization (WHO) recommends systematic TB screening followed by 1) confirmatory TB testing for all those who screen positive and 2) TB preventive therapy (TPT) for all TPT-eligible PLHIV who screen negative. The objective of the TB Screening Improves Preventive Therapy Uptake (TB SCRIPT) trial is to determine whether TB screening based on C-reactive protein (CRP) levels, measured using a rapid and low-cost point-of-care (POC) assay, improves TPT uptake and clinical outcomes of PLHIV, relative to symptom-based TB screening.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Tuberculosis screening improves preventive therapy uptake (TB SCRIPT) trial among people living with HIV in Uganda: a study protocol of an individual randomized controlled trial.
Semitala FC, Chaisson LH, Dowdy DW, Armstrong DT, et al · · 2022 · cited 7× · PMID 35550621 · DOI 10.1186/s13063-022-06371-0
Viral suppression among adults with HIV receiving routine dolutegravir-based antiretroviral therapy and 3 months weekly isoniazid-rifapentine.
Chaisson LH, Semitala FC, Nangobi F, Steinmetz S, et al · · 2023 · cited 5× · PMID 36779500 · DOI 10.1097/qad.0000000000003508
Healthcare-seeking behavior among people with HIV undergoing TB screening during the COVID-19 pandemic.
Aggarwal I, Chaisson LH, Opira B, Dowdy DW, et al · · 2024 · PMID 39035431 · DOI 10.5588/ijtldopen.24.0111

Verify or expand the search:

Other recruiting trials for Tuberculosis

Currently open trials in the same condition.

NCT05917210 — Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda · NA · recruiting
NCT07170735 — Quantitative Measurement of Plasma and Urine MTB Cell-free DNA Level · recruiting
NCT07484490 — Effects of the Active Cycle of Breathing Technique With and Without Balloon Blowing Therapy in Tuberculosis · NA · recruiting
NCT06318416 — Precision Rifampin Trial for Personalized Dosing · Phase 1 · recruiting
NCT07170800 — A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets · Phase 2 · recruiting

Other University of California, San Francisco trials

Trials by the same sponsor.

NCT05284773 — Screening for Acute Malnutrition · NA · withdrawn
NCT04634851 — Video Home Visits for Dietary Counselling · NA · not yet recruiting
NCT06065670 — Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a M · Phase 1, PHASE2 · not yet recruiting
NCT07534098 — Intervention for Hearing Health Among Native Americans · NA · not yet recruiting
NCT06960421 — Exercise-based Frailty Intervention in Lung Transplantation (XFIT) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04557176 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, San Francisco
Last refreshed: 10 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04557176.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing